Moreover, due to the loss of Tks4 having similar effects on cancer cells as EGF treatment (EMT induction, reduced E-cadherin expression), it is possible that Tks4 plays a putative negative regulatory role in the EGFR pathway by delaying signal transduction or changing its kinetics. The gene discussed is CDH1; the disease is cancer.